baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Axsome Therapeutics Inc/ US05464T1043 /

10/8/2024 8:09:29 PM	Chg. +1.3100	Volume	Bid10/8/2024	Ask10/8/2024	High	Low
85.4700USD	+1.56%	183,261 Turnover: 9.87 mill.	85.3800Bid Size: 400	85.5600Ask Size: 200	86.2300	84.1600

GlobeNewswire 8/27 Axsome Therapeutics to Participate in Investor Conferences in September

GlobeNewswire 8/21 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...

GlobeNewswire 8/11 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 8/5 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8/1 Compass Pathways announces second quarter 2024 financial results and business highlights

GlobeNewswire 7/25 Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Tre...

GlobeNewswire 7/11 Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire 6/26 Compass Pathways appoints Lori Englebert as Chief Commercial Officer

GlobeNewswire 6/5 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

GlobeNewswire 6/4 Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During...

GlobeNewswire 6/3 Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

GlobeNewswire 5/30 Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 5/29 Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function ...

GlobeNewswire 5/28 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Ps...

GlobeNewswire 5/8 Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 5/6 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/1 Axsome Therapeutics Recognizes May as Mental Health Awareness Month

GlobeNewswire 5/1 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 4/18 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 4/15 Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...

GlobeNewswire 4/12 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 4/10 Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire 4/4 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 4/1 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...

GlobeNewswire 3/26 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

Axsome Therapeutics Inc/ US05464T1043 /

If you wish to receive reply to your feedback, please provide your email address.